An injection containing the antiretroviral drug lenacapavir is highly effective at preventing HIV infection for six months per shot. This is according to top-line study findings announced last week by the pharmaceutical company Gilead. Detailed study findings have not yet been presented at a major scientific conference or published in a reputable scientific journal. To get more details about the effectiveness of this injection, I am joined on the line by…

GUEST: Professor Linda-Gail Bekker, Chief Executive Officer at Desmond Tutu Health Foundation